ADHD is a disorder that makes it difficult for a person to pay attention and control impulsive behaviors. He or she may also be restless and almost constantly active. ADHD is not just a childhood disorder. Although the symptoms of ADHD begin in childhood, ADHD can continue through adolescence and adulthood.
The Global Attention Deficit Hyperactivity Disorder (ADHD) market was valued at $ XX Mn in 2018 and is forecast to grow at a strong XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The market is driven by owing cumulative prevalence of ADHD. However, less availability of non-stimulants ADHD drugs is restraining market growth. Moreover, raising awareness regarding ADHD among physicians and patients is providing ample opportunities for the market
Attention Deficit Hyperactivity Disorder (ADHD) depending on drug type, Non-stimulants segment is expected to account for the largest share of the Attention Deficit Hyperactivity Disorder (ADHD) market due to their enduring effect equated to stimulants. The fact that these drugs present no risk of substance abuse is also a key factor to drive the segment development. Moreover, the rising number of market players have been investing in the development of non-stimulant drugs for attention-deficit/hyperactivity disorder, which is driving the segment
The Global Attention Deficit Hyperactivity Disorder (ADHD) market is segmented on the basis of Drug Type, Age Group, Distribution Channel and region.
By Drug Type: Stimulants and Non-stimulants
By Age Group: Adult and Pediatric and neonates
By Distribution Channel: E-commerce, Retail Pharmacies, Hospital Pharmacies, and Specialty Clinics.
By Region: North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market due to the large volume of drug prescriptions every year, increasing product launches, and rise in collaboration among players to enhance market penetration and for product development
The key players of the Global Attention Deficit Hyperactivity Disorder (ADHD) market include Eli Lily & Company, NEOS Therapeutics Inc, Prude Pharma L.P, Mallinckrodt, Shire, Johnson & Johnson Services, LLC, Pfizer, and Novartis AG
Report Description: The report covers in-depth analysis of the Global Attention Deficit Hyperactivity Disorder (ADHD) Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by Drug Type (Non-stimulants and Stimulants). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Attention Deficit Hyperactivity Disorder (ADHD) Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.